非肌层浸润性膀胱癌卡介苗治疗无效后的挽救性治疗研究进展  

Research progress in salvage treatment after failure of BCG for non-muscular invasive bladder cancer

作　　者：王印达 耿波[1] 李学东[1] WANG Yinda;GENG Bo;LI Xuedong(Department of Urology,the Second Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150000,China)

机构地区：[1]哈尔滨医科大学附属第二医院泌尿外科,黑龙江哈尔滨150000

出　　处：《现代肿瘤医学》2023年第22期4272-4279,共8页Journal of Modern Oncology

摘　　要：经尿道膀胱肿瘤电切术加术后辅助膀胱灌注卡介苗已成为现阶段非肌层浸润性膀胱肿瘤治疗的金标准,但仍有部分患者经卡介苗治疗后病情复发或进展。根治性膀胱切除术是卡介苗治疗无效患者的标准治疗方式,但部分患者无法或拒绝行膀胱根治性切除术,需要采取其他的挽救性治疗方式。本文通过分析目前经卡介苗治疗无效后挽救性治疗的相关文献总结了相关药物的使用和研究情况。除传统的膀胱内化疗,出现了许多新型药物和治疗方式,例如:改良卡介苗、免疫检查点抑制剂、热灌注治疗、光动力治疗、病毒基因治疗、靶向治疗、检查点抑制剂等。在未来,卡介苗治疗无效患者或许有更多的选择用以保留膀胱。Transurethral resection of bladder tumor combined with postoperative adjuvant bladder perfusion BCG has become the standard first-line treatment for non-muscular invasive bladder tumor at present.But there are still some patients with disease recurrence or progression after BCG treatment.Although radical cystectomy is the standard-of-care for patients failing BCG therapy,some patients are unable or unwilling to undergo radical cystectomy after failure of BCG treatment.They need to take other salvage treatment.In this paper,we review the literature on salvage treatment after failure of BCG treatment and summarize the use and research status of relevant agents.In addition to the traditional intravesical chemotherapy,many new treatments have emerged,such as modified BCG,immune checkpoint inhibitors,chemotherapy hyperthermia,photodynamic therapy,viral gene therapy,targeted therapy,checkpoint inhibitors and so on.New treatments may bring more choices and better outcomes for patients in the future.

关 键 词：非肌层浸润性膀胱癌 膀胱灌注治疗 卡介苗无效 挽救性治疗 

分 类 号：R737.14[医药卫生—肿瘤]